Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML-Reference-Cited by-同舟云学术

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Published:2017-04-27 Issue:17 Volume:129 Page:2384-2394
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Warfvinge Rebecca¹,Geironson Linda¹,Sommarin Mikael N. E.¹^ORCID,Lang Stefan¹,Karlsson Christine²,Roschupkina Teona¹,Stenke Leif³⁴,Stentoft Jesper⁵,Olsson-Strömberg Ulla⁶⁷,Hjorth-Hansen Henrik⁸⁹,Mustjoki Satu¹⁰¹¹,Soneji Shamit¹,Richter Johan²¹²,Karlsson Göran¹

Affiliation:

1. Division of Molecular Hematology, and

2. Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden;

3. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;

4. Department of Medicine, Karolinska Institutet, Stockholm, Sweden;

5. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;

6. Department of Medical Science, and

7. Division of Hematology, University Hospital, Uppsala, Sweden;

8. Department of Hematology, St. Olavs Hospital, Trondheim, Norway;

9. Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;

10. Hematology Research Unit Helsinki and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland;

11. Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; and

12. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

Abstract

Key Points Single-cell gene expression analysis reveals CML stem cell heterogeneity and changes imposed by TKI therapy. A subpopulation with primitive, quiescent signature and increased survival to therapy can be high-purity captured as CD45RA−cKIT−CD26+.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/17/2384/1400266/blood728873.pdf

Reference46 articles.

1. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia;de Klein;Nature,1982

2. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase;Schindler;Science,2000

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

4. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature,1973

5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial;Mahon;Lancet Oncol,2010

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09

2. BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?;Leukemia;2024-08-04

3. Immunophenotypic features of early haematopoietic and leukaemia stem cells;International Journal of Laboratory Hematology;2024-07-24

4. GAS2 Upregulation Is a Targetable Vulnerability in Chronic Myeloid Leukemia;International Journal of Translational Medicine;2024-06-15

5. Hallmarks of cancer stemness;Cell Stem Cell;2024-05